Page last updated: 2024-12-10

arachidonyl-2-chloroethylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

arachidonyl-2-chloroethylamide: a potent and selective agonist of the neuronal cannabinoid receptor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

arachidonyl-2'-chloroethylamide : A fatty amide obtained by the formal condensation of arachidonic acid with 2-chloroethanamine. It is a potent agonist of the CB1 receptor (Ki = 1.4 nM) and also has a low affinity for the CB2 receptor (Ki = 3100 nM). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311006
CHEMBL ID151167
CHEBI ID191854
SCHEMBL ID1517676
MeSH IDM0305548

Synonyms (30)

Synonym
(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid (2-chloro-ethyl)-amide
bdbm50072769
gtpl738
arachidonoyl-2-chloroethylamide
NCGC00162406-01
acea cpd
arachidonyl-2'-chloroethylamide
n-(2-chloroethyl)-5z,8z,11z,14z-eicosatetraenamide
n-(2-chloroethyl)-5,8,11,14-eicosatetraenamide
arachidonyl-2-chloroethylamide
CHEMBL151167 ,
L000112
(5z,8z,11z,14z)-n-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
CHEBI:191854
(5z,8z,11z,14z)-n-(2-chloroethyl)-5,8,11,14-eicosatetraenamide
acea
220556-69-4
SCHEMBL1517676
AKOS024456526
HMS3649N11
(5z,8z,11z,14z)-n-(2-chloroethyl)-5,8,11,14-icosatetraenamide
DTXSID60274346
273734-07-9
Q4783527
SR-01000946682-1
sr-01000946682
BA17966
GLXC-27067
CS-0032817
HY-110004

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In this study we compared the effects of CB1 and CB2 receptor-selective ligands, the endocannabinoid anandamide and the phytocannabinoid cannabidiol, against oxidative stress and the toxic hallmark Alzheimer's protein, β-amyloid (Aβ) in neuronal cell lines."( Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.
Harvey, BS; Mååg, JL; Musgrave, IF; Ohlsson, KS; Smid, SD, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of the study was to conduct an in vivo evaluation of the relationship between treatments with synthetic cannabinoid arachidonyl-2'-chloroethylamide (ACEA) alone or in combination with valproic acid (VPA) and hippocampal neurogenesis in a mouse pilocarpine model of epilepsy."( A Long-Term Treatment with Arachidonyl-2'-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy.
Andres-Mach, M; Dudra-Jastrzębska, M; Haratym, J; Haratym-Maj, A; Maj, M; Rola, R; Zagaja, M; Łuszczki, JJ, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
"05-5pmol) induced anxiolytic-like effects with bell-shaped dose-response curves, the higher doses being ineffective."( Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray.
Aguiar, DC; Guimarães, FS; Moreira, FA, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
CB1 receptor agonistA cannabinoid receptor agonist that binds to and activates type 1 cannabinoid receptors.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
CB2 receptor agonistA cannabinoid receptor agonist that binds to and activates type 2 cannabinoid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
fatty amideA monocarboxylic acid amide derived from a fatty acid.
synthetic cannabinoidA class of cannabinoid that consists of synthetic analogs of the naturally occuring cannabinoids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency25.11890.004023.8416100.0000AID485290
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency31.62280.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency39.81071.000012.232631.6228AID1452
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
DNA polymerase kappa isoform 1Homo sapiens (human)Potency28.18380.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)0.90000.00020.59827.0000AID346660
Cannabinoid receptor 1Homo sapiens (human)Ki0.00530.00010.50779.6000AID310543
Cannabinoid receptor 2 Homo sapiens (human)Ki0.09500.00000.415610.0000AID310544
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.31620.00411.89638.7000AID257800
Glutamate receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)0.31620.00411.62517.6000AID257800
Glutamate receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)0.31620.00411.17063.5000AID257800
Glutamate receptor 4Rattus norvegicus (Norway rat)EC50 (µMol)0.31620.00411.13393.5000AID257800
Cannabinoid receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.31620.00020.19211.9953AID257800
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1706257Agonist activity at CB1R in Sprague-Dawley rat hippocampal synaptosomes assessed as inhibition of 4-AP evoked glutamate release at 10 uM preincubated for 8 mins followed by 4-AP addition in presence of 1 uM CB2R antagonist, SR144528 by HPLC analysis2020European journal of medicinal chemistry, Dec-15, Volume: 208The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
AID49658Binding affinity towards cannabinoid receptor 1 from rat forebrain membranes in the absence of phenylmethanesulfonylfluoride (PMSF) using 0.8 nM [3H]CP-55940 as radioligand1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID310545Selectivity for human CB2 over human CB12007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
AID257800Displacement of [35S]GTP-gamma-S from rat cerebellar CB1 receptor2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
AID195417Effective concentration required for stimulation of [35S]GTP-gamma-S, binding in rat microsomal membranes1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID272968Displacement of [3H]CP-55940 from CB1 receptor in DBA/J2 mouse brain2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
AID1706254Agonist activity at CB1R in Sprague-Dawley rat hippocampal synaptosomes assessed as inhibition of 4-AP evoked glutamate release at 10 uM preincubated for 8 mins followed by 4-AP addition by HPLC analysis2020European journal of medicinal chemistry, Dec-15, Volume: 208The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
AID272969Displacement of [3H]CP-55940 from CB2 receptor in DBA/J2 mouse spleen2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
AID310543Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK293 cells2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
AID310544Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cells2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
AID1127514Selectivity ratio of Ki for CB2 receptor of rat spleen membranes to Ki for CB1 receptor of rat cerebellar membranes2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1127512Displacement of [3H]-CP55940 from CB1 receptor of rat cerebellar membranes by liquid scintillation counting in presence of serine protease inhibitor PMSF2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID195418Concentration required for stimulation of [35S]GTP-gamma-S, binding in rat microsomal membranes expressed as Emax1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID346660Inhibition of FAAH2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID1127513Displacement of [3H]-CP55940 from CB2 receptor of rat spleen membranes by liquid scintillation counting in presence of serine protease inhibitor PMSF2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID49854Binding affinity towards Cannabinoid receptor 2 from mouse spleen membranes using 0.8 nM [3H]CP-55940 as radioligand1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID195419Effective concentration required for stimulation of [35S]GTP-gamma-S, binding in rat microsomal membranes expressed as log EC501998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID272970Selectivity for DBA/J2 mouse CB2 receptor over CB1 receptor2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
AID1706280Agonist activity at CB1R in Sprague-Dawley rat hippocampal synaptosomes assessed as inhibition of 4-AP evoked glutamate release at 10 uM preincubated for 8 mins followed by 4-AP addition in presence of 1 uM CB1R antagonist, SR141716A by HPLC analysis2020European journal of medicinal chemistry, Dec-15, Volume: 208The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
AID49659Binding affinity towards cannabinoid receptor 1 from rat forebrain membranes in the presence of phenylmethanesulfonylfluoride (PMSF) using 0.8 nM [3H]CP-55940 as radioligand1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID1706281Agonist activity at CB1R in Sprague-Dawley rat hippocampal synaptosomes assessed as inhibition of glutamate release at 10 uM incubated for 8 mins by HPLC analysis2020European journal of medicinal chemistry, Dec-15, Volume: 208The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
AID1346753Rat CB1 receptor (Cannabinoid receptors)1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (150)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (1.33)18.2507
2000's54 (36.00)29.6817
2010's84 (56.00)24.3611
2020's10 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.91 (24.57)
Research Supply Index5.04 (2.92)
Research Growth Index6.32 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other150 (97.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]